Invesco Ltd. Akebia Therapeutics, Inc. Transaction History

Invesco Ltd.

$600 Billion
Q3 2025

A detailed history of Invesco Ltd. transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 2,400,757 shares of AKBA stock, worth $4.08 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,400,757

Previous 382,210 528.13%

Holding current value

$4.08 Million

Previous $1.39 Million 366.0%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$2.7 - $4.01 $5.45 Million - $8.09 Million	2,018,547 Added 528.13%	2,400,757 $6.48 Million
Q2 2025 Aug 13, 2025	BUY	$1.55 - $3.97 $188,490 - $482,779	121,607 Added 46.66%	382,210 $1.39 Million
Q1 2025 May 12, 2025	BUY	$1.69 - $2.84 $236,527 - $397,477	139,957 Added 116.01%	260,603 $500,000
Q4 2024 Feb 13, 2025	BUY	$1.26 - $2.13 $1,098 - $1,857	872 Added 0.73%	120,646 $224,000
Q3 2024 Nov 12, 2024	SELL	$0.94 - $1.55 $9,411 - $15,518	-10,012 Reduced 7.71%	119,774 $158,000

Q2 2024 Aug 13, 2024	BUY	$0.86 - $1.63 $89,397 - $169,440	103,951 Added 402.37%	129,786 $132,000
Q1 2024 May 14, 2024	SELL	$1.27 - $2.24 $4,236 - $7,472	-3,336 Reduced 11.44%	25,835 $47,000
Q4 2023 Feb 12, 2024	BUY	$0.8 - $1.28 $4,282 - $6,851	5,353 Added 22.47%	29,171 $36,000
Q3 2023 Nov 13, 2023	SELL	$0.87 - $1.84 $7,111 - $15,040	-8,174 Reduced 25.55%	23,818 $27,000
Q2 2023 Aug 11, 2023	BUY	$0.51 - $1.43 $16,315 - $45,748	31,992 New	31,992 $29,000
Q4 2022 Feb 13, 2023	SELL	$0.25 - $0.58 $1,254 - $2,909	-5,017 Reduced 2.0%	245,507 $142,000
Q3 2022 Nov 14, 2022	SELL	$0.3 - $0.46 $4,207 - $6,451	-14,026 Reduced 5.3%	250,524 $79,000
Q2 2022 Aug 15, 2022	SELL	$0.32 - $0.67 $4,930 - $10,323	-15,408 Reduced 5.5%	264,550 $93,000
Q1 2022 May 16, 2022	BUY	$0.72 - $2.93 $64,507 - $262,510	89,594 Added 47.06%	279,958 $201,000
Q4 2021 Feb 14, 2022	SELL	$2.26 - $3.34 $27,167 - $40,150	-12,021 Reduced 5.94%	190,364 $431,000
Q3 2021 Nov 15, 2021	BUY	$2.35 - $3.88 $35,633 - $58,832	15,163 Added 8.1%	202,385 $583,000
Q2 2021 Aug 17, 2021	BUY	$2.83 - $4.2 $73,894 - $109,666	26,111 Added 16.21%	187,222 $710,000
Q1 2021 May 17, 2021	BUY	$2.92 - $5.06 $383,728 - $664,954	131,414 Added 442.52%	161,111 $546,000
Q4 2020 Feb 16, 2021	SELL	$2.22 - $3.78 $1.28 Million - $2.18 Million	-576,649 Reduced 95.1%	29,697 $83,000
Q3 2020 Nov 16, 2020	SELL	$2.39 - $13.08 $1.16 Million - $6.36 Million	-486,094 Reduced 44.5%	606,346 $1.52 Million
Q2 2020 Aug 14, 2020	SELL	$6.67 - $13.58 $285,582 - $581,441	-42,816 Reduced 3.77%	1,092,440 $14.8 Million
Q1 2020 May 15, 2020	BUY	$4.1 - $10.24 $4.65 Million - $11.6 Million	1,135,256 New	1,135,256 $8.61 Million
Q2 2019 Aug 14, 2019	SELL	$4.1 - $8.05 $4.68 Million - $9.19 Million	-1,141,290 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$5.41 - $8.73 $6.17 Million - $9.96 Million	1,141,290 New	1,141,290 $9.35 Million

Others Institutions Holding AKBA

# of Institutions

189

Shares Held

121M

Call Options Held

267K

Put Options Held

280K

View Full List

About Akebia Therapeutics, Inc.

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $313M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

More about AKBA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account